S*BIO Receives BioSpectrum Editor’s Choice, Emerging BioScience Company of Singapore Award
The Annual BioSpectrum awards recognize outstanding contributions to the growth of the biotechnology and life sciences industry in
“We are proud to be named Singapore’s emerging bioscience company of the year,” said Dr.
“We thank everyone at S*BIO whose combined efforts led to the significant progress we made in moving our leading candidates, the JAK2 inhibitors SB1518 and SB1578, the HDAC inhibitor SB939, and the multi-kinase inhibitor SB1317, through pre-clinical and clinical development.”
Launched in 2003 by
About S*BIO Pte Ltd
S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO’s lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO’s potent and orally-active JAK2 inhibitor, also entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO’s SB1317, a novel multi-kinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization.
In line with its vision to be a leading fully-integrated oncology-focused biotech company in
S*BIO Pte Ltd: Russo Partners: Stephen Keith Rhind, Ph.D. Tony Russo +1 212-845-4251 Senior Vice President, Tony.Russo@russopartnersllc.com Corporate Development Tel: +65 6827 5000 (Singapore) Andreas Marathovouniotis +1 212-845-4235 Stephen_rhind@sbio.com Andreas.Marathis@russopartnersllc.com
SOURCE S*BIO Pte Ltd